New at WaveTec

Article

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

“The board appreciates Tom Berryman’s leadership and great contribution to the company's achievements, as well as his role in recruiting Tom Frinzi to the company. We are enormously pleased to welcome Tom to WaveTec,”said Charles Warden, of Versant Ventures a board member and investor in WaveTec. “Tom is a seasoned and dynamic leader who brings a wealth of proven commercial experience within the ophthalmic space. ”

Frinzi who began his career at Johnson & Johnson, is a 30 year veteran of the ophthalmic and medical device industries. Most recently, he served as Vice President of Global Commercial Operations at Bausch+Lomb Surgical where he was responsible for worldwide revenue of approximately $500 million generated via their cataract and vitreo‐retinal product portfolio.

“What attracted me to WaveTec is the potential to change the landscape of cataract surgery,” said Mr Frinzi. “What cornea topography was to refractive surgery, ORange can be to cataract surgery. The Premium Channel has raised expectations and WaveTec is uniquely positioned to help surgeons optimize their outcomes and ultimately improve the overall patient experience. That's exciting.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.